Quick Answer
Niagen Bioscience, Inc. reported Operating Income Loss of $16.28 million for the year ending 2025.
- Niagen Bioscience, Inc. showed an increase of +110.7% in Operating Income Loss from 2024 to 2025.
- This data is from Niagen Bioscience, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2012: -$3.99 million | Q3 2012: -$1.53 million | Q1 2013: -$1.42 million | Q2 2013: -$1.01 million | Q3 2013: -$1.24 million | Q4 2013: -$715.1 thousand | Q1 2014: -$1.84 million | Q2 2014: -$1.64 million | Q3 2014: -$647.4 thousand | Q4 2014: -$1.10 million | Q1 2015: -$906.1 thousand | Q2 2015: -$184.1 thousand | Q3 2015: $177.1 thousand | Q4 2015: -$1.24 million | Q1 2016: $32.1 thousand | Q2 2016: $158.8 thousand | Q3 2016: -$924.2 thousand | Q4 2016: -$2.17 million | Q1 2017: -$1.77 million | Q2 2017: -$2.65 million | Q3 2017: -$3.18 million | Q4 2017: -$8.78 million | Q1 2018: -$8.40 million | Q2 2018: -$7.94 million | Q3 2018: -$8.60 million | Q1 2019: -$8.37 million | Q2 2019: -$7.18 million | Q3 2019: -$6.89 million | Q1 2020: -$5.89 million | Q2 2020: -$3.69 million | Q3 2020: -$4.20 million | Q1 2021: -$7.36 million | Q2 2021: -$5.55 million | Q3 2021: -$8.84 million | Q1 2022: -$7.73 million | Q2 2022: -$6.39 million | Q3 2022: -$3.07 million | Q1 2023: -$1.97 million | Q2 2023: -$2.32 million | Q3 2023: -$1.15 million | Q1 2024: -$731.0 thousand | Q2 2024: -$256.0 thousand | Q3 2024: $1.60 million | Q1 2025: $4.77 million | Q2 2025: $3.19 million | Q3 2025: $4.24 million.
- Over the full 16 years of available data (2010 to 2025), Niagen Bioscience, Inc.'s Operating Income Loss has grown by 907.0%.
- Historical annual values: Fiscal year 2025: $16.28 million | Fiscal year 2024: $7.73 million | Fiscal year 2023: -$5.60 million | Fiscal year 2022: -$18.63 million | Fiscal year 2021: -$27.07 million | Fiscal year 2020: -$19.85 million | Fiscal year 2019: -$31.30 million | Fiscal year 2018: -$33.17 million | Fiscal year 2017: -$16.38 million | Fiscal year 2016: -$2.91 million | Fiscal year 2015: -$2.07 million | Fiscal year 2014: -$5.23 million | Fiscal year 2013: -$4.39 million | Fiscal year 2012: -$11.64 million | Fiscal year 2011: -$7.86 million | Fiscal year 2010: -$2.02 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: